139
Participants
Start Date
April 13, 2012
Primary Completion Date
November 9, 2019
Study Completion Date
November 9, 2019
FOLFOX + bevacizumab
Vitamin D
Vanderbilt-Ingram Cancer Center, Nashville
Mountain States Tumor Institute- Twin Falls, Twin Falls
Mountain States Tumor Institute- Fruitland, Fruitland
Mountain States Tumor Institute - Meridian, Meridian
Mountain States Tumor Institute- Nampa, Nampa
Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Lowell General Hospital, Lowell
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford
Newton-Wellesley Hospital, Newton
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, South Weymouth
New Hampshire Oncology Hematology-P.A., Concord
New Hampshire Oncology Hematology-P.A., Hooksett
New Hampshire Oncology Hematology-P.A., Laconia
Dana-Farber/New Hampshire Oncology-Hematology, Londonderry
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Dana-Farber Cancer Institute
OTHER